Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina


  • Shilpa B. N. Department of Pharmacology, JJMMC, Davangere, Karnataka, India
  • Shashikala G. H. Department of Pharmacology, JJMMC, Davangere, Karnataka, India
  • Siddesh . Department of Medical Gastroenterology, MIOT Hospital, Chennai, Tamilnadu, India
  • Mallesh P. Consultant Cardiologist, Bapuji Hospital, JJMMC, Davangere, Karnataka, India




CAD, Diabetes mellitus, FBS, HbA1c, Ranolazine


Background: Diabetes mellitus is the fifth leading cause of death worldwide and is one of the common co-morbid conditions associated with coronary artery disease (CAD). The overall prevalence of CAD is 7.4% but the prevalence of CAD in diabetics is 9%. Hence treatment of hyperglycemia is a key goal of secondary preventive therapy with a target of reducing HbA1c to <7%. The risk of CAD has been reported to occur 2 to3 decades prior in diabetics compared to non-diabetics. Hence discovery of drugs with potential role in both diabetes and CAD seems to be necessary. Ranolazine is a novel oral anti anginal drug known to reduce HbA1c and fasting blood glucose levels in angina patients with diabetes. The objective of this study is to show the effect of ranolazine (antianginal drug) on HbA1c and fasting blood glucose levels in diabetic patients with chronic angina.

Methods: Patients were divided into: Group 1 continued with previous antidiabetic drugs and antianginal drugs. Group 2 were prescribed Tab ranolazine 1000mg b.d (orally) as add on therapy along with previous antidiabetic drugs and antianginal drugs.

Results: There was a significant reduction in HbA1c and FBS levels in Group 2 patients who were on ranolazine. Reduction of HbA1c in group1 and Group 2 was 0.21±0.65% and 1.30±1.16% respectively. Reduction of FBS in group1 and group2 was 10.66±27.80mg/dl and 29.97±31.49mg/dl respectively.

Conclusions: From the present study we can conclude that ranolazine, an antianginal drug when given at a dose of 1000mg bd in diabetic patients with chronic angina reduces HbA1c and FBS levels.



King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414-31.

Powers AC. Diabetes mellitus complications. In: Kasper DL. Harrison’s principles of internal medicine, 19th ed. New York: Mc Graw hill education; 2015:2422-2423.

Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW; Atherosclerosis risk in communities study. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2005 Aug;28(8):1965-73.

Dodani S, Sharma G. Early Screening for coronary artery disease is needed in South Asian Indian immigrants with type 2 diabetes. Endocrinol Metabol Syndrome. 2001;S5:002.

Zachariah G, Harikrishnan S, Krishnan MN, Mohanan PP, Sanjay G, Venugopal K, et al. Cardiological Society of India Kerala Chapter Coronary Artery Disease and Its Risk Factors Prevalence (CSI Kerala CRP) Study Investigators. Prevalence of coronary artery disease and coronary risk factors in Kerala, South India: a population survey - design and methods. Indian Heart J. 2013 May-Jun;65(3):243-9.

Deshpande DA, Harris M, Schootman M. Epidemiology of diabetes and diabetes related complications. J Am Phy Ther Assoc. 2008;88:1254-64.

Olofsonk E, Cederholm J, Nilsson PM, Zelhelia BJ. New aspects of HbA1c as a risk factor for cardiovascular disease in type 2 diabetes; Intern med 2010 Nov;268(5):471-82.

American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30 Suppl 1:S4-S41.

Mohan V, Venkatraman JV, Pradeepa R. Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. J Diabetes Sci Technol. 2010;4(1):158-70.

Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163-8.

Timmis AD, Chaitman BR, Crager M.Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006 Jan;27(1):42-8.

Sandhiya S, Dkhar SA, Pillai AA, George M, Jayaraman B, Chandrasekaran A. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease-a randomized controlled trial. J Clin Diagn Res. 2015;9(1):OC01-5

Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Combination assessment of ranolazine in stable angina investigators. effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309-16.

Dhalla AK, Yang M, Ning Y, Kahlig KM, Krause M, Rajamani S, Belardinelli L ;Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects. Diabetes. 2014 Oct;63(10):3545-56.




How to Cite

N., S. B., H., S. G., ., S., & P., M. (2019). Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina. International Journal of Basic & Clinical Pharmacology, 8(3), 377–382. https://doi.org/10.18203/2319-2003.ijbcp20190647



Original Research Articles